MastroianniACiniselliCMPanellaRMacciottaACavalleriAVenturelliEet al
i vi ph n trung nin, iu ny ngha l da sn chc hn, t chy x gip bn t tin vi li sng nng ng
Novo Nordisk submitted an NDA (new drug application) to the FDA on December 18, 2025, which is the formal step companies take when seeking approval for a medication to be marketed for public use
BPC-157 vs KPV: Gastric Pentadecapeptide vs Anti-Inflammatory Tripeptide Comparison BPC-157 and KPV represent different approaches to tissue healing and inflammation control, with overlapping applications in gastrointestinal research
The Chinese government has included the NMPA-approved GLP-1 receptor agonists in the national medical insurance policy to increase the accessibility and affordability of such drugs
For Medicare beneficiaries who previously could not afford GLP-1 medications for weight loss, this is the first realistic path to coverage